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OBJECTIVES: To study the longitudinal trend (between 2000 and 2012) in substance 
use admissions among older adults, i.e., those aged 55 or older. METHODS: Using 
the Treatment Episode Data Set - Admissions (TEDS-A) for the period between 2000 
and 2012, we analyzed the trend in substance use admissions reported for older 
adults. Substance use admissions for older adults as a proportion of total sub-
stance use admissions were compared. Also, the trend in admission for primary 
substances such as cocaine/crack, marijuana/hashish, heroin, non-prescription 
methadone, other opiates and synthetics, methamphetamine, and benzodiazepines 
was compared. RESULTS: Of the total admissions for substance use in 2000, 3.4 
percent were attributable to older adults. Over time, there was a increase in this 
proportion and in 2012, 7.0 percent of all substance use admissions were accounted 
for by older adults. Older adults also exhibited sharp escalation in proportion of 
admissions between 2000-2012 where primary substance that led to admission 
was cocaine/crack (63% increase), marijuana/hashish (150% increase ), heroin (26% 
increase), non-prescription methadone (200% increase), other opiates and synthet-
ics (221% increase), methamphetamine (275% increase), and benzodiazepines (67% 
increase). CONCLUSIONS: It is important to note that though the total number of 
substance use admissions between 2000 and 2012 changed only a little, the propor-
tion of admissions attributable to older adults increased greatly. Among older adults, 
substance use is an important psychosocial co-comorbidity. Admissions for certain 
types of substances appear to be on the rise . Presence of substance use translates 
into treatment need. It can affect health outcomes and complicate management 
of other co-morbid conditions. Therefore, a surge in substance use in older persons 
coupled with aging of the US population has substantial implications for the entire 
healthcare system. There is an urgent need for appropriate preventive and treat-
ment polices aimed specifically towards older adults with a substance use disorder.
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OBJECTIVES: Analysis of the consumption of antibiotics plays a very important 
role in hospital care, since it allows the identification of areas where measures to 
improve the suitability for use and rationalization of resources should be adopted, 
stimulating improve the quality and development of surveillance strategies anti-
biotic resistance. The consumption of antibiotics in Slovak hospitals is still high 
compared with the other European countries. The aim of the study was to analyze 
the utilisation of antibiotics in the hospital sector in Slovakia. METHODS: Drug’s 
expenditure derived from the State Institute of Drug Control. Antibiotic drug con-
sumption was expressed as number of packages and as DDDs per 1000 inhabitants 
per day (DID). Data were analyzed according to ATC classification. RESULTS: During 
the period 2011 – 2014 was increased consumption of antibiotics - expressed as 
number of packages - in the ATC group J01D, in the community sector (primary 
care sector). By contrast, in the hospital pharmacies, the consumption gradually 
decreases. The Macrolides (J01F), one of the most prescribed antibiotics in commu-
nity sector reach 30% of the total volume consumed antibiotics in the community, 
in hospital sector but only 5%. While consumption of penicillins in hospital sector is 
increasing slightly (5% during the period), in the group of other beta-lactam antibiot-
ics, decrease (10 % during the period). CONCLUSIONS: According of the antibiotics 
costs demonstrated the development of consumption during the analyzed period 
decreasing trend. The decreasing consumption of antibiotics in community sector 
leads to increase of consumptions in hospital sector. The other analysis of consump-
tion at the hospital level should help health care providers to improve antibiotic use.
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OBJECTIVES: Drug-related problems (DRPs), prescribing pattern (PP) and poly-
pharmacy are identified as important risk factors in pharmaceutical care plan-
ning. This study was aimed to evaluate DRPs, PP and poly pharmacy issues in 
Pakistan. METHODS: A drug utilization-pattern regarding DRPs, PP and polyphar-
macy was evaluated at filling and refilling of the prescriptions written by registered 
medical practitioners and specialized physicians at local community pharmacies’ 
in a province, the Punjab, Pakistan. A stratified sample manner was adopted for 
selecting different community pharmacies. All of the prescriptions were ana-
lyzed according to WHO standard treatment guidelines for DRPs, PP and polyp-
harmacy. RESULTS: Among 900 observed prescriptions from different cities of the 
province, several DRPs, vague PP and polypharmacy issues were observed. Unfair 
numbers and types of drugs than the WHO recommendations were prescribed for 
each patient. Mean number of drugs in a single prescription were 5.0 (+1.6). The 
worth of prescribing indicators was much more than the WHO standard indica-
tors. A significant number of medicines (89%) were written in their brand names. 
Furthermore, the repeatedly prescribed medicines were antibiotics (55.1%), anxiolyt-
ics (22.4%), and corticosteroids (26%). CONCLUSIONS: Physicians’ adherence to the 
WHO standard prescribing guidelines was poor. Effecting apposite administrative 
dosing would be used to identify potential problem cases. The objective of this 
study was to evaluate the criteria being discussed by in this potential measure in 
Mississippi Medicaid. METHODS: A retrospective study was done using Mississippi 
Medicaid claims data for 2013. Beneficiaries were included if enrolled the entire 
year, had 1+ prescription for an opioid in the Center for Disease Control Morphine 
Milligram Equivalent Table, were age 19+, and they did not have any claims with 
diagnoses of sickle cell anaemia or cancer, were not dual eligible or in long term 
care. Morphine Equivalent Dose (MED) values were calculated for all prescriptions. 
Cut-off values of 120mg and 100mg MED were examined with sensitivity analysis 
for number of days at or above the cut-off. RESULTS: 1.37% and 2.24% of the benefi-
ciaries received prescriptions for opioids > 100mg MED for ≥ 60 and 30≥ consecutive 
days. 1.72% and 2.70% of the beneficiaries were found to receive prescriptions of 
opioids > 120mg MED for ≥ 60 and 30≥ consecutive days. Approximately, 1.77% of 
beneficiaries having an opioids prescription claims are consuming an MED greater 
than 120mg for more than 31 days indicating issues with their opioid consump-
tion pattern. 12.5% of beneficiaries having > 100mg MED for 30+ consecutive days 
were doctor shopping (using 4+ pharmacies and 4+ prescribers). CONCLUSIONS: 
Beneficiaries with high MED are at risk of becoming abusers, if they are not already. 
Use of MED limits in drug utilization review is a good method for identifying ben-
eficiaries at risk of becoming abusers. Combining doctor shopping with high MED 
can be used to identify potential abusers for intervention.
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OBJECTIVES: Bioequivalence studies are required for approval of generic medica-
tions and are regarded as a reliable methodology to evaluate equivalence of generic 
vs. branded products. However, recent issues with a few newly-launched generics 
highlight the need for post-marketing monitoring of generic medicines. Real world 
evidence uniquely available in pharmacy claims data can provide early detection of 
bioequivalence issues well before conventional methods (i.e. MedWatch).This study 
presents an analytic approach that uses pharmacy claims data to monitor possible 
bioequivalence issues with one generic version of the anti-depressant bupropion 
that was finally withdrawn from the market after studies failed to show bioequiva-
lence with the branded product. METHODS: Patient-level pharmacy claims data 
from Express Scripts, a pharmacy benefit manager (PBM) with over 90 million 
Americans, was used in a retrospective study evaluating patient persistence before 
discontinuation. Persistence was defined as the days from medication initiation to 
an instance of 45 days without therapy. Evaluations were done separately for 150 
and 300 mg bupropion and by manufacturer. RESULTS: With the 300 mg bupropion 
where bioequivalence was questioned, the percent of patients non-persistent at day 
360 was notably higher for some generic versions than for others. Manufacturer-
specific drop off rates were more similar for the 150 mg version where bioequiva-
lence was not questioned. Declining persistency among other generic providers 
was also observed, and could be due to awareness of the bioequivalence concerns 
among health professionals. CONCLUSIONS: The results demonstrate a decline 
in utilization of a specific generic anti-depressant medication that subsequently 
failed bioequivalence testing, supporting the use of large PBM claims databases with 
access to real-time product utilization details. Leveraging consumer information 
early in the generic launch process can provide insights into bioequivalence leading 
to improved patient care through early detection and enhance Health Economic and 
Outcomes Research (HECOR) and Market Researcher Post Launch strategy.
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OBJECTIVES: Just over 7 million Americans enrolled in private insurance through 
the new health insurance exchanges in 2014. The exchange plans are required to 
cover essential health benefits, including prescription drugs, although the generos-
ity of prescription drug coverage in exchange plans has not been well described, 
nor compared to employer-sponsored insurance. METHODS: We examined the 27 
federally facilitated exchanges and 7 partnership exchanges, for which character-
istics of all plans on the exchanges were publicly available from data.gov for 2014. 
For comparison we also provide additional results for the 2015 plans. We com-
pared the exchanges with data from the Kaiser Family Foundation/Health Research 
Educational Trust’s annual employer survey. Descriptive analyses of exchange plans 
quantifying plan characteristics including extent of copayments or coinsurance, 
number of pharmacy benefit tiers, average copayment/coinsurance in each for-
mulary tier, and deductible amounts. RESULTS: Within the exchanges, we find 
wide variation in the out-of-pocket costs enrollees will face for generic, preferred 
brand, non-preferred brand and specialty drugs, both across metal tiers and across 
plan type within metal tier. Coinsurance is used instead of copayments for many 
drugs in the upper pharmacy formulary tiers (e.g. Specialty drugs). Compared to 
employer sponsored plans, these exchange plans generally have lower premiums, 
but provide less generous coverage. Cost sharing subsidies for low income indi-
viduals may mitigate the higher out of pocket costs found in many silver exchange 
plans. CONCLUSIONS: On average, exchange plans had lower premiums than 
employer-sponsored insurance plans, but higher deductibles and cost sharing for 
prescription drugs. The gold and platinum-level PPO plans were more generous 
than employer-sponsored coverage on average. Decision tools to assist consumers 
in selecting plans on more attributes than just premium will also be key in helping 
individuals avoid high out of pocket burdens.
